Is Bypassing Traditional Weight-Loss the Answer for Atrial Fibrillation?
نویسندگان
چکیده
منابع مشابه
Atrial fibrillation: is NO an answer for refractoriness?
The progressive nature of atrial fibrillation (AF) has been attributed to alteration in the electrophysiological properties of the atrial myocardium. As a net effect, a shortening in the refractory period contributes to the substrate, allowing ectopic complex arising and re-entry [1]. Transmembrane ion channel activity determines atrial action potential (AP) shape. Whereas Na and Ca channels ar...
متن کاملObesity-driven endometrial cancer: is weight loss the answer?
Endometrial cancer is the fourth most common cancer affecting British women, behind breast, lung and colon cancer. Over the past 20 years, the incidence of endometrial cancer has risen by 40%, and deaths by 20%, despite improved overall survival rates. Currently more than 1900 British women die from endometrial cancer each year, compared with fewer than 1500 at the turn of the century. The agin...
متن کاملObesity and atrial fibrillation: the evidence is gaining weight.
The occurrence of atrial fibrillation (AF) is associated with a substantial increase in risk of death, stroke, and heart failure. The increasing incidence of the arrhythmia in the general population further underscores its public health relevance. Reasons for the increasing AF incidence include the advancing age of the population and a better survival among individuals with structural heart dis...
متن کاملLoss of atrial contractility is primary cause of atrial dilatation during first days of atrial fibrillation.
Atrial fibrillation (AF) induces a progressive dilatation of the atria which in turn might promote the arrhythmia. The mechanism of atrial dilatation during AF is not known. To test the hypothesis that loss of atrial contractile function is a primary cause of atrial dilatation during the first days of AF, eight goats were chronically instrumented with epicardial electrodes, a pressure transduce...
متن کاملHow much atrial fibrillation is too much atrial fibrillation?
n engl j med 366;2 nejm.org january 12, 2012 178 tive anti-HER2 agents as adjuvant therapies may translate into metastatic disease developing in fewer patients. Given the success of the pivotal trials of adjuvant trastuzumab therapy, clinical trials of adjuvant therapies, which are already large and expensive, will by necessity require even more subjects to detect small differences with a new a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation: Arrhythmia and Electrophysiology
سال: 2019
ISSN: 1941-3149,1941-3084
DOI: 10.1161/circep.119.007864